Your Source for Venture Capital and Private Equity Financings

Venture Capital News: Talaris Therapeutics Inks $115M Series B

2020-10-06
BOSTON, MA, Talaris Therapeutics has announced the closing of a $115 million Series B financing.
Talaris Therapeutics, a privately held biotechnology company developing transformative cell therapies that have the potential to induce durable immune tolerance across a range of indications, announced the closing of a $115 million Series B financing co-led by Surveyor Capital (a Citadel company) and Viking Global Investors.

Other participants in the financing included new investors Cormorant Asset Management, Invus, funds and accounts managed by BlackRock, Eventide Asset Management, Logos Capital, Aisling Capital and Pamoja Capital, as well as Talaris' Series A investors Blackstone Life Sciences, Longitude Capital and Qiming Venture Partners USA.

Talaris Therapeutics, Inc. is a late-clinical stage biotechnology company that is developing transformative cell therapies with the potential to eliminate the burden of chronic immunosuppression for organ transplant recipients as well as induce durable remissions in patients with severe autoimmune and immune-mediated disorders. Talaris is backed by a number of leading life sciences investors and maintains corporate offices in Boston, Mass., and its cell processing facility in Louisville, Ky. www.TalarisTx.com.
(c) by Massinvestor, Inc. For contact info, please check out our about page.
>> Click here for in-depth research on 9,000+ startups and 5,000+ VC investors